Updated: ‘Ruthless’ pipeline prioritization, obesity and China: Three takeaways from AstraZeneca’s Q4
LONDON — AstraZeneca on Thursday morning teased its vision on how it could potentially enter the obesity market, as well as its views on further China-based deals. The giant pharma also unveiled five pipeline cuts across its metabolic, rare disease and oncology portfolios.
“We have had to really ruthlessly prioritize our R&D projects” to focus on “the most promising opportunities,” CEO Pascal Soriot said during an in-person press event in London for its fourth-quarter earnings.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.